tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Geoff Meacham, 177 are a BUY (56.19%), 106 are a HOLD (33.65%), 32 are a SELL (10.16%).
Analyst Geoff Meacham, currently employed at BAML, carries an average stock price target met ratio of 66.51% that have a potential upside of 29.89% achieved within 226 days.
Geoff Meacham’s has documented 669 price targets and ratings displayed on 54 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on ABBV, AbbVie at 03-Feb-2025.
Analyst best performing recommendations are on BTAI (BIOXCEL THERAPEUTICS).
The best stock recommendation documented was for BTAI (BIOXCEL THERAPEUTICS) at 1/7/2025. The price target of $7 was fulfilled within 1 day with a profit of $0.54 (7.16%) receiving and performance score of 71.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
3 years 9 months 16 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
3 years 9 months 18 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
3 years 9 months 26 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 17 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 1 months 14 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Geoff Meacham is most bullish on?
Which stock is Geoff Meacham is most reserved on?
What Year was the first public recommendation made by Geoff Meacham?
